Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2695)	11/8/1997 11:34:00 AM
From: Izzy	Read Replies (1) of 6136

Dr. Oliver: Thank you for the excellent report and follow-up. A few questions: 1) Are any other parameters being used besides CD4 counts and viral loads 2) Is a 3 drug combo treatment being recommended as initial treatment for asymptomatc HIV 3) Is the prognosis (morbidity/mortality) improved for those who respond to 3 drug regimens (ie., is aggressive initial therapy indicated and is the the patient's clinical status an important factor [ie., CDC class, Karnofsky score] 4) How often should CD4 counts and viral loads be done and are meds adjusted depending on results? Thanks in advance.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next